Roche Holding

Roche ups the ante in obesity

12/03/25 -"Roche and Zealand Pharma have agreed to co-develop and co-commercialise Zealand’s phase II weight-loss drug candidate, petrelintide, as monotherapy and in combination with Roche’s ..."

PDF page sample
Pages
66
Language
English
Published on
12/03/25
Download
You may also be interested by these reports :
20/10/25
“Only when the tide goes out do you discover who’s been swimming naked.” This famous line from Warren Buffett fits well for the ...
17/10/25
The markets were jubilant with Virbac’s Q3 25 beat and a guidance upgrade, especially because the investors, in September 2025, doubted the firm’s ...
06/10/25
Over the week ending 3 October, equity markets delivered another strong performance. In Europe, the STOXX 600 rose 2.9%, driven by a massive rebound ...
03/10/25
We have materially upgraded our earnings estimates for UCB, keeping in view the vigorous uptake of the immunology drug Bimzelx, and a strong support ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO